GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

GSK. “Our SWIFT and ANCHOR trials support depemokimab’s potential to suppress interleukin-5, a known driver of type 2 inflammation, to offer patients sustained inhibition of a key driver of ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application for the use of depemokimab in two indications. The proposed ...

Also Read: GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review ICER President and CEO Sarah K. Emond emphasized the significance of the report, highlighting that over 15 ...

GSK plc announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application for the use of depemokimab in two indications. The proposed indications are as add ...